NASDAQ:EVGN - Evogene Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 228.72 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.89
▼ -0.02 (-0.69%)

This chart shows the closing price for EVGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVGN

Analyst Price Target is $9.50
▲ +228.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evogene in the last 3 months. The average price target is $9.50, with a high forecast of $10.00 and a low forecast of $9.00. The average price target represents a 228.72% upside from the last price of $2.89.

This chart shows the closing price for EVGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Evogene.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2021AegisInitiated CoverageBuy$10.00Medium
11/30/2020Cantor FitzgeraldInitiated CoverageOverweight$9.00High
8/17/2016Credit Suisse GroupLower Price TargetOutperform$19.00 ➝ $10.00N/A
(Data available from 8/5/2016 forward)
Evogene logo
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $2.89
Low: $2.80
High: $3.00

50 Day Range

MA: $3.33
Low: $2.82
High: $3.95

52 Week Range

Now: $2.89
Low: $1.08
High: $10.24

Volume

477,757 shs

Average Volume

286,841 shs

Market Capitalization

$74.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Evogene?

The following equities research analysts have issued reports on Evogene in the last twelve months: Aegis, Cantor Fitzgerald, and Zacks Investment Research.
View the latest analyst ratings for EVGN.

What is the current price target for Evogene?

2 Wall Street analysts have set twelve-month price targets for Evogene in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 228.7%. Aegis has the highest price target set, predicting EVGN will reach $10.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $9.00 for Evogene in the next year.
View the latest price targets for EVGN.

What is the current consensus analyst rating for Evogene?

Evogene currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVGN will outperform the market and that investors should add to their positions of Evogene.
View the latest ratings for EVGN.

What other companies compete with Evogene?

How do I contact Evogene's investor relations team?

Evogene's physical mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company's listed phone number is 972-8931-1900 and its investor relations email address is [email protected] The official website for Evogene is www.evogene.com.